Group 1 - The CCB 50 ETF Guolian (159965) opened at 1.627 yuan, with a slight increase of 0.12% [1] - Major holdings in the ETF include China Ping An, which fell by 0.02%, and other companies like Industrial and Commercial Bank of China, which dropped by 0.41%, and Hengrui Medicine, which decreased by 1.52% [1] - The ETF's performance benchmark is the CCB Financial 50 Index return, managed by Guolian Fund Management Co., with a return of 62.69% since its establishment on March 19, 2019, and a recent one-month return of -3.32% [2] Group 2 - A MACD golden cross signal has formed, indicating potential upward momentum for certain stocks [3]

Group 1: High-end Manufacturing - In January-February 2026, the export value of electric tools, hand tools, and lawn mowers increased by 7%, 53%, and 38% year-on-year, respectively, with lawn mower exports to Europe rising by 57% [1] - Exports of forklifts, machine tools, industrial sewing machines, and mining machinery grew by 25%, 16%, 13%, and 32% year-on-year, indicating a strong performance in the high-end machinery sector [1] - The report suggests focusing on companies like Juxing Technology and Jingjin Equipment due to their strong export performance in the European market [1] Group 2: Petrochemical Industry - Satellite Chemical's profitability is enhanced by rising oil prices, leading to an upward revision of net profit forecasts for 2026-2028 to 7.588 billion, 8.739 billion, and 9.292 billion yuan, respectively [2] - The report maintains a "buy" rating for Satellite Chemical, reflecting confidence in its supply chain advantages amid high oil prices [2] - CNOOC Development reported a 6.2% year-on-year increase in net profit for 2025, with expectations for net profits of 4.465 billion, 4.938 billion, and 5.337 billion yuan for 2026-2028 [3] Group 3: Steel Industry - Fangda Special Steel's revenue for 2025 was 18.233 billion yuan, down 15.43% year-on-year, but the company is focusing on high-margin products and optimizing its product structure [4] - The forecast for net profit from 2026 to 2028 is set at 1.13 billion, 1.24 billion, and 1.36 billion yuan, maintaining an "overweight" rating due to its unique position in the rebar market [4] Group 4: Automotive and Robotics - Shuanglin Co., Ltd. met performance expectations for 2025 and plans to fully enter the humanoid robot and intelligent chassis markets in 2026 [5] - The net profit forecast for 2026-2028 has been adjusted to 610 million, 720 million, and 840 million yuan, reflecting a cautious outlook amid increasing competition [5] Group 5: Electric and New Energy - Sifang Co., Ltd. achieved a revenue increase of 17.87% to 8.193 billion yuan in 2025, with a net profit rise of 15.84% to 829 million yuan [7] - The company is actively expanding into the AIDC market and international markets, which is expected to support future growth [7] Group 6: TMT Sector - Changfei Optical Fiber and Cable, a global leader, is well-positioned for growth driven by AI demand and has a strong production capacity [8] - The company is expected to see significant revenue growth from its subsidiaries, indicating a positive outlook for its business [8] - SenseTime reported a 32.9% increase in revenue for 2025, with a substantial reduction in net losses, driven by growth in its generative AI business [9] - The revenue forecast for 2026-2028 has been adjusted to 6.43 billion, 8.28 billion, and 10.74 billion yuan, reflecting strong growth potential [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月25日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江苏恒瑞医药股份有限公司 2025 年年度报告 公司代码：600276 ...

Group 1: Company Strategy and Business Focus - The company is committed to focusing on its core business, emphasizing the "big health" development strategy in pharmaceuticals and healthcare [2] - In pharmaceuticals, the company aims to enhance its integrated development model, covering raw materials, formulations, functional skincare products, and skin health management [2][3] - The healthcare segment includes basic medical care, rehabilitation, and longevity services, creating a comprehensive health ecosystem for customers [2][4] Group 2: Pharmaceutical Business Overview - The pharmaceutical business involves the research, production, and sales of drug formulations and raw materials, with a focus on skin, anti-infection, and anti-tumor products [3] - The company has three raw material production bases, ensuring a stable supply of core products and establishing long-term partnerships with international pharmaceutical companies [3] - The company holds a 13.2% stake in a gene therapy company, making it the third-largest shareholder [3] Group 3: Healthcare Services - The healthcare services include basic medical treatment, rehabilitation, and health management, providing integrated services to improve patient health and longevity [4][5] - The company operates various medical institutions that collaborate on resources, technology, and training to enhance service quality [7] Group 4: Tourism Business - The tourism segment includes operations in scenic area transportation, hotel management, and tourism performances, primarily in five major 5A scenic spots [9] - The company aims to enhance its core competitiveness and improve management levels across its business segments, including tourism [9] Group 5: Financial Performance Projections - For 2025, the company expects a net profit attributable to shareholders between 66 million and 73 million, representing a year-on-year growth of 320.74% to 344.16% [9] - The net profit after excluding non-recurring gains is projected to be between 60 million and 67 million, indicating a growth of 277.59% to 298.31% compared to the previous year [9]

Group 1: Oil Crisis Historical Review and Investment Insights - The oil crisis typically begins with geopolitical conflicts and escalates due to expectations of supply disruptions, leading to short-term price spikes and long-term price increases [1][12] - The macroeconomic impact of oil crises has historically led to inflation followed by stagnation or similar conditions, with the 1970s crisis resulting in recession and stagflation in the US, while the 2022 situation only saw a technical recession [1][12] - Market narratives have evolved, reflecting learning effects from past crises, with shifts from valuation model failures to asset worship and supply-side reforms [1][12] - Asset performance during crises shows that commodities like oil benefit directly, while equities face valuation pressures, and bonds initially decline before rising due to inflation expectations [1][12] Group 2: Logistics and Transportation Sector - The daily traffic volume at Ganqimaodu Port has shown a steady recovery, with an average of 1,351 vehicles per day from March 16 to March 22, 2026, marking a 55.7% year-on-year increase [5][17] - The port's cargo throughput has also increased significantly, with a 35% year-on-year growth to 10.24 million tons as of March 15, 2026 [5][17] - Short-distance freight rates have stabilized and increased, averaging 65 RMB per ton in 2026, reflecting an 8.3% year-on-year rise [6][17] Group 3: Company-Specific Insights - Jiayou International reported a revenue of 2.486 billion RMB in Q3 2025, a 30.61% year-on-year increase, driven by the recovery of cross-border business and rising prices of coking coal [7][18] - The company is expected to benefit from the integration of mining services, logistics, customs clearance, and coal sales, enhancing its competitive advantage in the cross-border logistics market [7][18] - Northern International is projected to benefit from rising coking coal and European natural gas prices, with a target price of 18 RMB based on a 24x PE ratio for 2026 [31][32] Group 4: Social Services Sector - The social services sector is experiencing a policy-driven boost in consumer spending, particularly in travel and hospitality, with recommendations for various hotel and tourism companies [19][20] - The education sector is also seeing robust demand, with significant expansion opportunities in high school education and vocational training [20][23] - Traditional retail is undergoing transformation, with new consumption patterns emerging and companies adapting to changing market dynamics [20][23]

Market Overview - The Hang Seng Index is expected to hold at 23,700 points due to prolonged geopolitical uncertainties and rising oil prices, with inflation risks increasing [1] - The economic growth target for mainland China has been slightly adjusted to a range of 4.5% to 5%, aligning with expectations, while the short-term likelihood of stimulus measures appears low [1] Sector Focus - AI stocks are anticipated to perform well as AI models undergo intensive upgrades, contributing to rapid growth in the semiconductor industry [2] - Energy stocks are benefiting from the ongoing Middle East tensions, which are driving up oil and coal prices [2] Corporate News - Alibaba's new flagship processor, the XuanTie C950, has been unveiled [3] - Xiaomi reported a 44% increase in adjusted net profit, meeting expectations, with new SU7 orders exceeding forecasts [3] - Nongfu Spring's net profit grew by 30.9% year-on-year, surpassing expectations [3] - China Telecom's annual net profit was 33.2 billion RMB, up 0.5%, but fell short of expectations [3] - WuXi Biologics reported a 46% increase in profit, exceeding expectations [3] Economic Indicators - The U.S. Federal Reserve maintained interest rates, reflecting a cautious stance, with economic growth forecasts slightly raised to 2.4% for the year [3] - The inflation forecast was adjusted upward to 2.7% due to ongoing geopolitical uncertainties [3] - The report from the Boao Forum predicts a 4.5% growth for the Asian economy this year, slightly lower than last year's 4.7% [6] International Developments - The U.S. is considering a one-month ceasefire to negotiate a 15-point agreement with Iran, which has implications for oil prices [7] - Japan is evaluating its oil supply chain in response to the Iranian conflict and plans to release national oil reserves [8] - The World Gold Council anticipates increased gold purchases by central banks as geopolitical risks rise [8]

Group 1: Market Overview - The market is experiencing a volume-constrained rebound, indicating short-term stabilization [5][8] - The overall A-share market saw a rise of 2.11%, with the Shanghai Composite Index increasing by 1.78% to close at 3881.28 points [8] - The small-cap stocks outperformed larger stocks, with the CSI 1000 index rising by 2.59% [9] Group 2: Industry Dynamics - In February 2026, the online market for smart locks in China saw a decline in both volume and revenue, with sales dropping by 7.0% to 539,000 units and revenue decreasing by 14.7% to 430 million yuan [25] - The price of LCD TV panels is expected to rise in March, with small and medium sizes increasing by $1 and large sizes by $2-3 [27] - Alibaba's new flagship processor, the Xuantie C950, was released, claiming to be the highest-performing RISC-V CPU globally [29] Group 3: Company Updates - Zhonghong Medical plans to increase its investment in the Indonesian nitrile glove project from 1.092 billion yuan to 1.477 billion yuan [33] - Sanquan Foods announced a share repurchase plan, intending to buy back shares at a price not exceeding 13.50 yuan per share, with a total fund of 75 million to 150 million yuan [36] - Lijiang Co. reported a revenue increase of 6.42% year-on-year for 2025, reaching 860 million yuan, with a net profit growth of 1.24% [38] - Xinlitai received approval for clinical trials of its innovative drug SAL0145, which shows potential for treating MASH [39] - Huqin Technology reported a revenue of 171.437 billion yuan for 2025, with a net profit increase of 38.55% [42]

Market Overview - Middle East conflict escalated, leading to significant market volatility with the Hang Seng Index dropping 894 points (3.5%) to close at 24,382 points[1] - The Hang Seng Tech Index fell by 159 points (3.3%) to 4,712 points, with total market turnover increasing to 368.7 billion HKD from 342.5 billion HKD the previous day[1] - Major tech stocks like Tencent and Alibaba saw declines of 1.9% and 3.2% respectively, reflecting worsening market sentiment[1] Oil and Gold Market - International oil prices rose, benefiting China National Offshore Oil Corporation (CNOOC) which increased by 0.4%[1] - Gold prices fell below 4,100 USD/ounce, erasing all gains since the beginning of the year, with Zijin Mining and Zhaojin Mining dropping 5.0% and 3.4% respectively[1] Automotive Sector - XPeng Motors reported a 38% year-on-year revenue increase in Q4, achieving a gross margin of 21.3% and a non-GAAP net profit of 510 million CNY, marking its first profitable quarter[3] - Other automotive stocks like Geely and Chery saw gains between 0.4% and 2.7% despite broader market declines[3] Energy Sector - The renewable energy and utility sectors experienced widespread declines, particularly affected by rising energy prices, with companies like China Gas and Xinyi Solar facing cost pressures[3] Pharmaceutical Sector - The pharmaceutical industry also fell in line with the market, with China National Pharmaceutical Group reporting a revenue of 575.17 billion CNY, a 1.6% year-on-year decline, while net profit increased by 1.5% to 7.16 billion CNY[4]

Core Viewpoint - The latest QFII holdings in A-shares reveal a strategic shift towards specific sectors such as pharmaceuticals, semiconductors, and manufacturing, indicating a targeted investment approach rather than a return to traditional blue-chip stocks [1][9]. Group 1: QFII Holdings Overview - As of March 22, 41 listed companies are included in the QFII heavy holdings list, with 77 holding records from 16 foreign institutions [1]. - Major active foreign institutions include UBS, Barclays, Morgan Stanley, Goldman Sachs, and JPMorgan, with sovereign wealth funds like Abu Dhabi Investment Authority and Kuwait Investment Authority focusing on pharmaceuticals, energy, and manufacturing [1][7]. Group 2: Investment Trends - QFII holdings are primarily concentrated in sectors such as pharmaceuticals, semiconductors, hardware, machinery, electrical equipment, and chemicals, with manufacturing being the main focus [1][9]. - The investment strategy reflects a preference for niche manufacturing, pharmaceuticals, and technology chains, moving away from traditional large-cap stocks [1][9]. Group 3: Specific Stock Movements - Abu Dhabi Investment Authority increased its stake in Baofeng Energy by 40,000 shares, bringing its total to 44.81 million shares, valued at 880 million yuan [2][6]. - New positions were established by UBS in companies like Demingli and Zhongxing Junye, while Morgan Stanley entered positions in Jin Haitong and Dazhi Shares [3][6]. Group 4: Sector-Specific Insights - The semiconductor and hardware sectors are highlighted, with companies like Demingli and Jin Haitong attracting significant foreign interest [9][10]. - In the pharmaceutical sector, companies such as Xin Nuowei and Huazhong Sanjiu are noted for their foreign holdings, indicating a diverse investment across traditional and growth-oriented pharmaceutical companies [11]. Group 5: Overlapping Holdings - Notable overlap in holdings exists, with Dazhi Shares being held by five foreign institutions, while *ST Songfa, Zhejiang Liming, and Shuhua Sports are held by four [8]. - This trend indicates a concentrated interest in specific stocks within the semiconductor, equipment manufacturing, automotive parts, and pharmaceutical sectors [8].

Group 1 - The core viewpoint of the report highlights that the Beijing Stock Exchange (BSE) has reached a milestone of 300 listed companies, with over 55% being "little giants" and 65 single champions, establishing a strong foundation for new productive forces [2][11][18] - The BSE has shown a steady increase in the number of specialized and innovative small and medium-sized enterprises, with the proportion of national-level "little giants" rising from 44% to 55.33% as the number of such companies grew from 44 to 99 [2][18][19] - The report indicates that the 300 listed companies are primarily concentrated in advanced manufacturing and strategic emerging industries, which are crucial for enhancing the capital market's role in empowering new productive forces and addressing supply chain deficiencies [2][28] Group 2 - The report notes that the average and median revenue for companies queued for listing in 2024 are projected to be 791 million and 588 million respectively, indicating a high-quality pipeline of future listings [2][39] - The distribution of companies by revenue shows that 32.85% of the queued companies are expected to generate revenue between 5-10 billion, while 25.12% are anticipated to exceed 10 billion [29][31] - The report emphasizes that the BSE's focus on "specialized, refined, unique, and innovative" enterprises is creating a market ecosystem that supports the growth of these companies, which are characterized by their unique products and advanced technologies [15][18] Group 3 - The report highlights that the BSE's market performance has been affected by rising risk premiums, with the North Certificate 50 and specialized new index experiencing declines of 5.76% and 7.57% respectively [3][57] - The valuation metrics for various sectors indicate that high-end equipment, chemical new materials, and biomedicine have significant valuation advantages compared to information technology, with respective P/E ratios of 36.58X, 44.08X, and 32.34X [3][65] - The report suggests that the BSE is positioned to enhance its market appeal by attracting high-quality specialized and innovative enterprises, particularly in sectors that are currently underrepresented compared to other boards like the Sci-Tech Innovation Board and the Growth Enterprise Market [45][49]